- Measurements9
- Endpoints5
- Domains3/5
- Products1
- No matrix stability evidence
- 2 clearance measurements
- Product-level review pending
- No sequence liability cues
Open the matching evidence section below
Sequence & molecular identity
1 formsReviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.
This peptide currently has identity-level evidence, but no reviewed sequence, HELM, or SMILES representation for residue-level interpretation.
Structure & chemistry
Chemical representationnone
How the current release can interpret this identity chemically.
plain sequence-likeResidue string used for positional interpretation when available.
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
3D structure referencesnone attached
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
Covalent topology & modifications1 signal
| Feature | Positions | Interpretation | Link |
|---|---|---|---|
| Form-level topology | ATLPF0025461 | Disulfide-constrained form. Residue-level connection endpoints are shown separately when available. | Not linked |
Physicochemical profile
6 descriptorsComputed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.
These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.
Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.
Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.
Computed logP — distinct from the measured logD endpoint.
1 Ro5 violation · MW 540.71 Da
Exposure / Absorption
4 recordsWhat evidence describes systemic exposure or absorption?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
AUC2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | Observation The geometric mean AUC inf values in patients with mild, moderate, and severe hepatic impairment were approximately 144%, 114%, and 116% of the corresponding value in patients with normal hepatic function, respectively. | Interpret as reported | human | Result: Qualitative or narrative result · Molecular form: ATLPF0025461 · Romidepsin· 12.3 Pharmacokinetics · romidepsin hepatic impairment auc context text · The... · Source: Primary reference linked | Reference |
| 2 | 1549 ng*h/mL | Use only explicitly reported fields | human · plasma | Result: Reported point value · Molecular form: ATLPF0025461 · Route: intravenous · Romidepsin· 12.3 Pharmacokinetics · geometric mean cmax auc respectively auc · 12.3 Pharm... · Source: Primary reference linked | Reference |
Cmax2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | Observation the geometric mean C max values after administration of 14, 7, and 5 mg/m 2 romidepsin in patients with mild (B1: bilirubin ≤ULN and AST >ULN; B2: bilirubin >ULN but ≤1.5 x ULN and any AST), moderate (bilirubin >1.5 x ULN to ≤3 x ULN and any AST), and severe (bilirubin >3 x ULN and any AST) hepatic impairment were approximately 111%, 96%, and 86% of the corresponding value after administration of 14 mg/m 2 romidepsin in patients with normal (bilirubin ≤upper limit of normal (ULN) and aspartate aminotransferase (AST) ≤ULN) hepatic function, respectively. | Interpret as reported | human | Result: Qualitative or narrative result · Molecular form: ATLPF0025461 · Romidepsin· 12.3 Pharmacokinetics · romidepsin hepatic impairment cmax context text · the... · Source: Primary reference linked | Reference |
| 2 | 377 ng/mL | Use only explicitly reported fields | human · plasma | Result: Reported point value · Molecular form: ATLPF0025461 · Route: intravenous · Romidepsin· 12.3 Pharmacokinetics · geometric mean cmax auc respectively cmax · 12.3 Phar... · Source: Primary reference linked | Reference |
Distribution / Barrier
3 recordsWhat is known about distribution, binding, permeability, or barrier crossing?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 1.2 L/kg | Eligible when experimental context matches | Volume of distribution at steady state in human after iv administration · human | Result: Reported point value · Molecular form: not reported · Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... · Source: Primary reference linked | Reference |
Plasma protein binding2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 92-94 % | Use only explicitly reported fields | human · plasma | Result: Interval measurement · Molecular form: ATLPF0025461 · Romidepsin· 12.3 Pharmacokinetics · plasma binding highly bound in plasma percent range ·... · Source: Primary reference linked | Reference |
| 2 | 92-94 % | Use only explicitly reported fields | plasma protein | Result: Interval measurement · Molecular form: not reported · Route: IV · 78 · Romidepsin · exact product name match · exact or normalized match · Source: Primary reference linked | Source record |
Barrier and permeability assay context
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Excretion / Persistence
2 recordsWhat evidence describes clearance or persistence?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Clearance2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 7.4 mL/min/kg | Eligible when experimental context matches | Clearance in human after iv administration · human | Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name ROMID... · Source: Primary reference linked | Reference |
| 2 | Observation Romidepsin clearance decreased with increased severity of hepatic impairment. | Interpret as reported | human | Result: Qualitative or narrative result · Molecular form: ATLPF0025461 · Romidepsin· 12.3 Pharmacokinetics · romidepsin hepatic impairment clearance decreased tex... · Source: Primary reference linked | Reference |
Evidence landscape
9 recordsCross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.
A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.
Top evidence-bearing endpoint questions.
Broad context buckets, useful before comparing values.
Reference-link availability for measurement-level audit.
Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.
| # | ADMET domain | Endpoint | Reported value | Result type | Analysis use | Assay / model | Condition | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | Distribution / Barrier Distribution | Plasma Protein Binding | 92-94 % | Interval measurement | Use only explicitly reported fields | plasma protein | Route: IV | Source record Primary reference linked |
| 2 | Distribution / Barrier Distribution | Volume Of Distribution | 1.2 L/kg | Reported point value | Eligible when experimental context matches | Volume of distribution at steady state in human after iv administration · human | Route: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein | Reference Primary reference linked |
| 3 | Excretion / Persistence Persistence | Clearance | 7.4 mL/min/kg | Reported point value | Eligible when experimental context matches | Clearance in human after iv administration · human | Route: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein | Reference Primary reference linked |
| 4 | Exposure / Absorption Exposure | Max Concentration | 377 ng/mL | Reported point value | Use only explicitly reported fields | human · plasma | Route: intravenous | Reference Primary reference linked |
| 5 | Exposure / Absorption Exposure | Area Under Curve | 1,549 ng*h/mL | Reported point value | Use only explicitly reported fields | human · plasma | Route: intravenous | Reference Primary reference linked |
| 6 | Excretion / Persistence Persistence | Clearance | Observation Romidepsin clearance decreased with increased severity of hepatic impairment. | Qualitative or narrative result | Interpret as reported | human | Not specified | Reference Primary reference linked |
| 7 | Exposure / Absorption Exposure | Max Concentration | Observation the geometric mean C max values after administration of 14, 7, and 5 mg/m 2 romidepsin in patients with mild (B1: bilirubin ≤ULN and AST >ULN; B2: bilirubin >ULN but ≤1.5 x ULN and any AST), moderate (bilirubin >1.5 x ULN to ≤3 x ULN and any AST), and severe (bilirubin >3 x ULN and any AST) hepatic impairment were approximately 111%, 96%, and 86% of the corresponding value after administration of 14 mg/m 2 romidepsin in patients with normal (bilirubin ≤upper limit of normal (ULN) and aspartate aminotransferase (AST) ≤ULN) hepatic function, respectively. | Qualitative or narrative result | Interpret as reported | human | B2: bilirubin >ULN but ≤1.5 x ULN and any AST), moderate (bilirubin >1.5 x ULN to ≤3 x ULN and any AST), and severe (bilirubin >3 x ULN and any AST) hepatic impairment were approximately 11... | Reference Primary reference linked |
| 8 | Exposure / Absorption Exposure | Area Under Curve | Observation The geometric mean AUC inf values in patients with mild, moderate, and severe hepatic impairment were approximately 144%, 114%, and 116% of the corresponding value in patients with normal hepatic function, respectively. | Qualitative or narrative result | Interpret as reported | human | Not specified | Reference Primary reference linked |
| 9 | Distribution / Barrier Distribution | Plasma Protein Binding | 92-94 % | Interval measurement | Use only explicitly reported fields | human · plasma | Not specified | Reference Primary reference linked |
Product context
1 productsProduct-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.
Summary1 linked product
- Linked products
- 1
- Label context
- None
- Clinical trials
- 25
- Safety label cues
- None
Linked products1 shown
Romidepsin
Identity & reference map
9 sourcesReference-level support for checking reported names, sequence notation, and peptide identity agreement.
Summary3 reference groups
- Identity type
- modified or textual identity
- Reported notation
- 1
- Reference groups
- 3
- Measurements
- 9
- ATL peptide ID
- ATLPC0028808
Identity concordance
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.
vcXVXX
No sequence representation
Reference map3 reference groups
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding | No reported alias | 6 identity 6 evidence |
Reference | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 2 identity 2 evidence |
Source record | Distribution Plasma Protein Binding | No reported alias vcXVXXdifferent | 1 identity 1 evidence |
Data access & reproducibility
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Record scopePublic release
- ATL peptide ID
- ATLPC0028808
- Identity type
- modified or textual identity
- ADMET endpoints
- 5
- Evidence records
- 9
- Reference groups
- 3
- Release view
- Public release
Data access
Structured peptide profile
JSONPeptide-specific profile used by this page, including identity and evidence context.
Peptide catalogue
TSVComplete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.
Measurement catalogue
TSVComplete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.
Programmatic access
The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0028808' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'